Spanish venture capital firm Ysios Capital has launched a €100m second life sciences fund.
Led by Joël Jean-Mairet, managing partner, Ysios BioFund II will support European and North American companies developing products, platforms or technologies in the pharmaceutical and medtech and diagnostics segments.
This is the second fund managed by Ysios Capital. Its first €69m Ysios BioFund I invested in 10 companies, exiting BioVex (sold to Amgen for up to $1 billion) and Endosense (sold to St. Jude Medical for up to CHF325m), and floating adult stem cell therapy company Cellerix on the NYSE Euronext Brussels through a reverse merger with Tigenix.
the Ysios BioFund II portfolio will include up to 15 companies co-investing with other specialized international investors and corporate venture funds.
FinSMEs
21/03/2014